Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the...
Nhwa Pharmaceutical
Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered...
Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation...
Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in...
Jiangsu Nhwa Pharmaceutical Gets NMPA Green Light for Schizophrenia Drug Trial
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a China-based pharmaceutical company, has announced that it...
Jiangsu Nhwa Pharmaceutical Receives NMPA Approval for Olinvyk (Oliceridine) Injection
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a China-based pharmaceutical company, has announced that it...
Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine
China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...